Several investment firms have updated their stock ratings and price targets on shares of Eli Lilly & Co. (NYSE: LLY) in the last week:

  • Eli Lilly & Co. had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $42.00 price target on the stock.
  • Eli Lilly & Co. was upgraded by analysts at Goldman Sachs from a “sell” rating to a “neutral” rating. They now have a $54.00 price target on the stock, up previously from $42.00. They wrote, “We upgrade LLY to Neutral from Sell, as new solanezumab data provides a backbone for the recent “hope trade”. Our skepticism was proven wrong as the data presented at ANA today demonstrates that the beta amyloid thesis is alive and well and that sola could conceivably reach the market in 3-4 years. We raise our price target to $54 on increased pipeline, in addition to Alimta likely remaining on the market for another 5 years.”
  • Eli Lilly & Co. had its “neutral” rating reaffirmed by analysts at UBS AG.
  • Eli Lilly & Co. had its price target raised by analysts at Bank of America to $57.00. They now have a “buy” rating on the stock.
  • Eli Lilly & Co. was downgraded by analysts at Cowen from a “neutral” rating to an “underperform” rating.
  • Eli Lilly & Co. had its “underperform” rating reaffirmed by analysts at Jefferies Group. They now have a $36.00 price target on the stock.
  • Eli Lilly & Co. was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating.

Eli Lilly & Co. traded up 4.12% on Monday, hitting $52.53. Eli Lilly & Co. has a 52-week low of $35.46 and a 52-week high of $53.55. The company has a market cap of $58.765 billion and a price-to-earnings ratio of 13.98.

Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.